Earnings Releases·Oct 30, 2026, 7:42 AM ET

OmniAb — Third Quarter 2026 Earnings Summary

Q3 2026 revenue rose to $4.0 million from $2.2 million year-over-year, while year-to-date revenue reached $31.8 million compared to $10.3 million in 2025; net loss narrowed to $15.7 million ($0.12/share) in Q3 from $16.5 million ($0.14/share) and $29.3 million ($0.23/share) year-to-date from $50.6 million ($0.46/share).
Full-year 2026 revenue guidance was raised to $35–$39 million (from $32–$36 million), with operating expense guidance lowered to $83–$87 million and cash costs to $50–$54 million, projecting year-end cash reserves of $53–$57 million.
Strategic growth was driven by a new global collaboration with Eli Lilly for an ion channel program (up-front payment plus up to $370 million in milestones), the launch of the OmniTides peptide discovery offering, and the October 2026 commercial expansion of the xPloration platform to all customers.
Deferred revenue increased significantly to $14.973 million as of September 30, 2026, from $3.161 million at year-end 2025, supported by 111 active partners and 433 active programs, including 34 clinical and commercial programs derived from OmniAb.